Evolus, Inc.

Evolus, Inc. Earnings Recaps

EOLS Health Care 1 recap
Q3 2025 Nov 10, 2025

Evolus delivered a strong third quarter with a 13% revenue increase driven by robust demand for Jeuveau and promising early results from the Evolysse launch, positioning the company for sustainable profitability by 2026.

Key takeaways
  • Jeuveau unit sales grew consistently, achieving a 14% share of the U.S. market.
  • Evolysse generated $5.7 million in revenue during its third quarter, marking the strongest debut for a HA filler in over a decade.
  • The Evolus Rewards program saw total redemptions rise 34%, reinforcing consumer loyalty with 70% of members being repeat customers.
  • The company remains focused on efficiency as it prepares to bundle products, encouraging cross-selling while expanding its customer base to over 17,000 accounts.